Policy & Regulation
ERS Genomics licenses Nobel prize winning CRISPR technology to Otsuka Pharmaceutical
3 March 2021 -

Biopharma solution company ERS Genomics Limited said on Tuesday that it has entered into a license agreement for its CRISPR/Cas9 genome editing technology with Otsuka Pharmaceutical Co Ltd.

The agreement provides Otsuka with access to ERS Genomics' CRISPR/Cas9 genome editing technology for its internal research and development initiatives to address areas of unmet medical need.

Based in Dublin, Ireland, ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr Emmannuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

Financial details of the agreement are not disclosed. Summit Pharmaceuticals serves as the exclusive agent for ERS Genomics in Japan.



Related Headlines